Lead Sponsor

Hoffmann-La Roche

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

No

•Overtly healthy as determined by medical evaluation that includes medical history and physical examination
•Agreement to adhere to the contraception requirements described in the protocol
•Active treatment-naïve macular neovascularization (MNV) secondary to age-related macular degeneration (AMD), confirmed by the investigator based on the presence of intraretinal fluid (IRF) or subretinal fluid (SRF) affecting the central subfield on optical coherence tomography (OCT)
•BCVA of 83 to 24 letters, inclusive (20/25 to 20/320 approximate Snellen equivalent, using the early treatment diabetic retinopathy study \[ETDRS\] protocol and addressed at the initial testing distance of 4 meters on Day 1)
•Sufficiently clear ocular media and adequate pupillary dilation to allow acquisition of good quality retinal images to confirm diagnosis

•MNV due to causes other than nAMD, such as ocular histoplasmosis, trauma, pathological myopia, angioid streaks, choroidal rupture, or uveitis
•Retinal pigment epithelial tear involving the macula on Day 1
•Current vitreous hemorrhage on Day 1
•Prior periocular pharmacological or IVT treatment (including faricimab, anti-vascular endothelial growth factor \[VEGF\], or complement inhibitor medication) for other retinal diseases
•Participants who have a nonfunctioning fellow (non-study) eye, defined as either BCVA of hand motion or worse, or no physical presence of non-study eye (i.e., monocular), at both the screening and study Day 1 visits
•Ocular Exclusion for Both Eyes:
•History of idiopathic or autoimmune associated uveitis in either eye
•Active ocular inflammation or suspected or active ocular or periocular infection in either eye on study Day 1

Related studies

NCT07308639 · Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)

NCT05210803 · Neovascular Age-Related Macular Degeneration (nAMD), Gene Therapy, and more

NCT06929143 · Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)

NCT06075147 · Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD), and more

NCT04514653 · Neovascular Age-Related Macular Degeneration (nAMD)

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration